REN and congenital adrenal hyperplasia: Interestingly, a 6-month MR-HC therapy in patients with SW-CAH resulted in a reduction of plasma renin activity and an increase in sodium levels, suggesting more effective mineralocorticoid action, likely due to decreased concentrations of 17OHP, a known mineralocorticoid receptor antagonist (298).